Clinical trial NCT02223923: Phase I Study to Assess Safety of AZD6738 Alone and in Combination With Radiotherapy in Patients With Solid Tumours
Official title: A Phase I Study to Assess the Tolerability, Safety and Biological Effects of ATR Inhibitor (AZD6738) as a Single Agent and in Combination With Palliative Radiation Therapy in Patients With Solid Tumours
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE1
Conditions: Solid Tumour Refractory to Conventional Treatment
Keywords: Phase 1
Maximimum tolerated dose
ATR Inhibitor
Radiotherapy
Lead sponsor: Royal Marsden NHS Foundation Trust
Sponsor class: OTHER
Collaborators: name: AstraZeneca
name: Cancer Research UK
name: RM/ICR Biomedical Research Centre
First posted: 2014-08-22
Enrollment: 87
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study will investigate the use of a new drug targeting the DNA repair pathway AZD6738, an ATR inhibitor). Many tumours have lost important DNA repair functions and rely more heavily on a few remaining repair pathways to survive. Preclinical studies indicate that, in these tumours, preventing the function of the remaining pathways will lead to tumour cell death, while sparing normal cells. This study aims to investigate the safety and tolerability of the new drug in patients with advanced cancer, as well as in combination with palliative radiotherapy, where the drug may increase the effectiveness of radiotherapy by preventing repair of the radiationinduced DNA damage. As the drug has only been given to a small number of patients, the study will focus on safety and finding the correct dose to proceed to further studies, although preliminary signs of drug activity will also be examined.

The initial part of the study will administer increasing doses of the drug to groups of patients with advanced cancer who have no standard anticancer treatment options available. Testing will establish whether the drug levels in the body and tumour are adequate for the drug to have an effect, and any toxicity will be assessed. After the recommended dose is established, the recommended dose schedule will be stablished by trialing different schedules. Participants will be tested to see if their tumours lack the main DNA repair pathway (those who are predicted to have a better response to this drug). Finally, the drug will be given to patients with advanced cancer who require a course of radiotherapy for symptom control - the drug will be tested at different doses and with different doses of radiotherapy.

Side effects will be monitored and tests will establish whether the drug is enhancing the radiotherapy effect in the tumours or normal tissues.


Eligibility criteria: Inclusion Criteria:

* Histologically or cytologically documented solid tumour refractory to conventional treatment
* Evidence of measurable or evaluable disease by RECIST 1.1
* Age must be 18 years or over.
* ECOG performance status 0-1 (part A); 0-2 (parts B and C)
* Life expectancy of at least 3 months.
* Patients must have normal organ and bone marrow function measured within 7 days prior to administration of study treatment as defined below:
* Signed informed consent indicating that the subject is aware of the neoplastic nature of their disease and have been informed of the procedures to be followed, the experimental nature of the therapy, alternatives, potential benefits, side effects, risks, and discomforts.
* Willing and able to comply with scheduled visits, tissue sampling, treatment plan, and laboratory tests.
* Able to swallow, absorb and retain oral medication.

Exclusion Criteria:

* Therapy with any other investigational medical product (IMP) concurrently or within 28 days prior to signing of consent.
* Pregnant or breast-feeding women.
* Ability to become pregnant (or already pregnant or lactating).
* Clinically significant cardiac disease including:
* Known HIV positive or active hepatitis B or C infection
* Uncontrolled active infection
* Symptomatic and progressive or steroid-requiring brain metastases or leptomeningeal disease involvement.
* Uncontrolled hypertension requiring clinical intervention, hypertension requiring 2 or more antihypertensive agents
* Dementia or altered mental status that would prohibit informed consent.
* Other severe, acute, or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration or may interfere with the interpretation of study results and, in the judgment of the Principal Investigator, would make the subject inappropriate for this study.

Primary outcomes:
measure: Identifying the maximum tolerated dose (MTD) of AZD6738 as a single-agent; and in combination with palliative radiation schedules.
timeFrame: 4 weeks
Secondary outcomes:
measure: Determining causality of each adverse event in relation to AZD6738 and grading severity according to CTCAE version 4;
timeFrame: 4 weeks
measure: Single and multiple dose pharmacokinetics: measurement of plasma levels of AZD6738 at pre-defined intervals in the dose-escalation part of the study in order to establish pharmacokinetic parameters;
timeFrame: Day 0 and Day 1
measure: Any response (stable disease, partial response or complete response) in any of the patients by physical, tumour marker and/or radiographic assessments of tumours as determined by RECIST 1.1.
timeFrame: 8 weeks
Other outcomes:
Locations:
city: London
country: United Kingdom
facility: University College Hospital
city: London
country: United Kingdom
facility: Guys and St Thomas' NHS Foundation Trust
city: London
country: United Kingdom
facility: Royal Marsden Hospital
Study officials:
affiliation: Institute of Cancer Research, United Kingdom
name: Kevin Harrington, MBBS MRCP FRCR
role: PRINCIPAL_INVESTIGATOR
affiliation: University College London Hospitals
name: Martin Forster
role: PRINCIPAL_INVESTIGATOR
References: